<DOC>
	<DOC>NCT02280616</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of a low and high dose of a budesonide effervescent tablet and oral viscous budesonide suspension vs. placebo for the induction treatment of active eosinophilic esophagitis.</brief_summary>
	<brief_title>Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Major Signed informed consent Male or female patients, 18 to 75 years of age Confirmed clinicopathological diagnosis of EoE according to established diagnostic criteria: (A) Clinical symptoms of esophageal dysfunction (B) Peak eosinophils â‰¥ 15 in at least 1 highpower field (hpf) Active symptomatic and histological EoE at baseline Major Clinically and endoscopically suspicion for gastroesophageal reflux disease, achalasia, or sklerodermia Gastroesophageal reflux disease and PPIresponsive esophageal eosinophilia Other clinical evident causes than EoE for esophageal eosinophilia Any concomitant esophageal disease and relevant gastrointestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection) Any relevant systemic disease (e.g., AIDS, active tuberculosis) Abnormal hepatic function at screening visit, liver cirrhosis, or portal hypertension Abnormal renal function at screening History of cancer in the last five years (except for nonmetastatic cancers, e.g., basalioma) History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit Upper gastrointestinal bleeding within 8 weeks prior to screening visit Concomitant, or within the 4 weeks prior to screening visit, treatment with systemic therapies for any reason that may affect assessment of primary and secondary endpoints, i.e., systemic glucocorticoids, histamine antagonists, mast cell stabilizers, leukotriene receptor antagonists, biologics, or immunosuppressants Concomitant, or within the 2 weeks prior to screening visit, treatment with topical therapies for any reason that may affect assessment of primary and secondary endpoints, i.e., topical glucocorticoids or inhaled sodium cromoglycate Installation of dietary restrictions within 4 weeks prior to screening visit or during treatment Intake of grapefruit containing food or beverages during the treatment with study medication Known intolerance/hypersensitivity to study drug Existing or intended pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>